Please note: The information displayed on this page might be outdated.
Locanabio: Developr of RNA-targeting gene therapy intended to address a wide spectrum of human genetic diseases with platform technology. The company's technology consists of an advanced and powerful modular RNA targeting-effector approach to address the root cause of genetic disease, enabling medical practitioners to optimize and advance therapeutic candidates that are distinct from DNA-targeted approaches and nucleic acid-based RNA targeting.
US - Pacific
Central Nervous System, Ophthalmology
San Diego, CA
Company Participants at Winter Private Company Showcase
Locanabio, Chief Business Officer
Micah joined Locanabio in April 2020 as Chief Business Officer. He joins us from Assembly Biosciences, where he served as Senior Vice President, Corporate Development and Strategy leading business development efforts since 2015. Prior to Assembly, he was Senior Director, Corporate Investment at Jabil Healthcare & Life Sciences, where he led healthcare transactions. Previously, Micah served as Head of Corporate Strategy and Senior Director, New Ventures at H. Lundbeck A/S, focused on neuroscience. Prior to the acquisition by Lundbeck, he was Director, Corporate Development and M&A at Ovation Pharmaceuticals, a rare disease, neuroscience company that launched the first product for Huntington’s Disease. Micah previously held financial roles at Eli Lilly and Pfizer. Micah earned a Bachelor of Science degree in Finance from Indiana University.